112366-39-9

Usage

Imidazole ring

A 5-membered aromatic ring with two nitrogen atoms at positions 1 and 3, contributing to its stability and potential biological activity.

Carboxylic acid group

A functional group (-COOH) that provides acidity and can form hydrogen bonds, which may influence solubility and reactivity.

Methyl ester

A functional group (-COOCH3) derived from the esterification of the carboxylic acid group, which can affect the compound's reactivity and volatility.

3-[1-(3,4-dichlorophenyl)propyl] side chain

A structural feature that extends from the imidazole ring, containing a 3,4-dichlorophenyl group and a propyl chain, which may contribute to the compound's biological activity and selectivity.

Thioxo group

A sulfur-oxygen double bond (-S(=O)-) that is isoelectronic with an oxo group (-C(=O)-), potentially influencing the compound's reactivity and stability.

Potential pharmaceutical applications

The presence of various functional groups and the dichlorophenyl group suggests that 1H-Imidazole-4-carboxylic acid, 3-[1-(3,4-dichlorophenyl)propyl]-2,3-dihydro-2-thioxo-, methyl ester may have biological activity, making it a potential candidate for drug development or as an intermediate in the synthesis of biologically active compounds.

Use as a research starting material

Due to its unique structure and functional groups, 1H-Imidazole-4-carboxylic acid, 3-[1-(3,4-dichlorophenyl)propyl]-2,3-dihydro-2-thioxo-, methyl ester may be used as a starting material for the synthesis of other important compounds in chemical research.

Need for further analysis and experimentation

The specific properties, reactivity, and uses of 1H-Imidazole-4-carboxylic acid, 3-[1-(3,4-dichlorophenyl)propyl]-2,3-dihydro-2-thioxo-, methyl ester are not fully known and require additional investigation to determine its potential applications and limitations.

Upstream product

• 107-31-3 Methyl formate 
• 333-20-0 potassium thioacyanate 
• 847448-00-4 {[1-(3,4-dichloro-phenyl)-propyl]-formyl-amino}-acetic acid methyl ester 
• 847448-34-4 [1-(3,4-dichloro-phenyl)-propylamino]-acetic acid methyl ester 

Downstream Products

• 742107-78-4 C₁₃H₁₂Cl₂N₂O₂S 
• 742107-77-3 C₁₃H₁₄Cl₂N₂OS 
• 742107-81-9 C₁₄H₁₄Cl₂N₂O₂S 
• 742107-82-0 C₁₄H₁₄Cl₂N₂O₂S 
• 871343-71-4 C₁₅H₁₄Cl₂N₄OS 
• 871343-28-1 3-[1-(3,4-dichloro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carbonyl chloride 
• 742107-78-4 3-[1-(3,4-dichloro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carboxylic acid 
• 871343-40-7 C₂₂H₂₂Cl₂N₂O₃S 

Relevant academic research and scientific papers

MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-66alkyl, C3-7cycloalkyl, C1-66alkylo xyC1 -6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 represents hydrogen, cyano, optionally subst ituted C1-66alkyl, C(=O)-O-R5, C(=O)-NR6aR6b, C(=S)-NR6aR6b, S(=O)2-NR6aR6b or C(=O)-R7; R4 represents hydrogen or C1-6alkyl; n is 1, 2, 3, 4 or 5; Z represents a cyclic ring system. The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.

2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca

MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I),a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl or heteroaryl; R2 is halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; R4 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; n is 1, 2, 3, 4 or 5;provided that at least one of R3 or R4 is other than hydrogen; and that if R3 represents C(=O)-OH, C(=O)-O-C1-6alkyl or C(=O)-O-C2-6alkenyl, then R4 is other than hydrogen; and that if R3 represents CH2OH and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents C(=O)-NH-C1-4alkyl-NH2 and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents formula (II) and R1 represents hydrogen, then R4 is other than hydrogen; having CCR2 receptor antagonistic properties. The invention also relates to processes for preparing the compounds of formula (I) and pharmaceutical compositions comprising them.